Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fel-O-Vax Lv-K
- Development stage
- Unknown
- Lead developer
- Elanco
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intramuscular
01
Overview
Fel-O-Vax Lv-K is an adjuvanted, monovalent vaccine containing whole inactivated (killed) feline leukemia virus (FeLV). Originally developed by Fort Dodge Animal Health and now part of the Elanco animal health portfolio, it is designed for the active immunization of healthy cats 10 weeks of age or older against Feline Leukemia Virus. FeLV is a retrovirus known to cause severe immunosuppression, anemia, and various forms of cancer in feline populations. The vaccine stimulates the feline immune system to recognize viral proteins, thereby preventing persistent infection and viremia following exposure to the pathogen. Clinical trials have demonstrated high efficacy, with preventable fractions reaching up to 100% in certain challenge studies. It is typically administered via subcutaneous or intramuscular injection as a two-dose primary series followed by annual revaccination.
- Brand names
- Fel-O-Vax Lv-KTruFel FeLV
- Other names
- Feline leukemia virus vaccineFel-O-Vax LvKFeline leukemia virus vaccine, killed virus
Beyond the preview
Go deeper on Fel-O-Vax Lv-K.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fel-O-Vax Lv-K.